From GlobeNewswire: 2025-05-08 07:00:00

Rapport Therapeutics, Inc. is progressing well with its RAP-219 Phase 2a trials in patients with refractory focal epilepsy and bipolar mania, with topline results expected in 2025 and 2027, respectively. The company reported $285.4 million in cash to fund operations through 2026. A new Investor and Analyst Day is scheduled for June 2, 2025, featuring key presentations.

RAP-219 PET data showed selective expression in epilepsy-associated brain regions, with receptor occupancy for seizure protection achieved within five days. The drug demonstrated favorable tolerability in four Phase 1 trials. Topline results for the Phase 2a trial in patients with refractory focal epilepsy are expected in the third quarter of 2025.

The Phase 2a trial for patients with bipolar mania remains on track to begin in the third quarter of 2025, with results expected in the first half of 2027. Plans for a Phase 2a trial in Diabetic Peripheral Neuropathic Pain are underway, with an update expected in 2025. Dr. Jeffrey Sevigny has been appointed as the Chief Medical Officer.

Financially, Rapport reported a net loss of $24.1 million for the first quarter of 2025, with $19.6 million in R&D expenses and $7.5 million in G&A expenses. The company ended the quarter with $285.4 million in cash, cash equivalents, and short-term investments, enough to fund operations through the end of 2026.

Rapport Therapeutics is a clinical-stage biotech company focused on developing precision medicines for neurological and psychiatric disorders. Their lead drug, RAP-219, targets specific brain regions associated with epilepsy, bipolar disorder, and peripheral neuropathic pain. The company’s innovative approach aims to provide differentiated treatments for patients in need.



Read more at GlobeNewswire:: Rapport Therapeutics Reports First Quarter 2025 Financials